{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARA+C&page=36",
    "query": {
      "intervention": "ARA C",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 906,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARA+C&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARA+C&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T09:12:58.689Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00007852",
      "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2000-09-01",
      "completion_date": "2011-01-01",
      "has_results": false,
      "last_update_posted_date": "2023-09-01",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00007852"
    },
    {
      "nct_id": "NCT00574080",
      "title": "UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Interim/Maintenance Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Adriamycin",
          "type": "DRUG"
        },
        {
          "name": "InductionConsolidation Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Induction/Consolidation Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Induction Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Adriamycin",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 and 2 Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Autologous Peripheral Blood Stem Cell Transplant (ASCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Transplant 2 Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Transplant 2 Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 and 2 Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Transplant 1 and 2 Thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2006-07",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-11-20",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574080"
    },
    {
      "nct_id": "NCT03718143",
      "title": "AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibroses",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Combination AZD1775 with AraC",
          "type": "DRUG"
        },
        {
          "name": "AZD1775 only",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 6,
      "start_date": "2019-05-08",
      "completion_date": "2019-09-27",
      "has_results": true,
      "last_update_posted_date": "2020-06-02",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03718143"
    },
    {
      "nct_id": "NCT00065143",
      "title": "Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Ara-C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "50 Years to 74 Years"
      },
      "enrollment_count": 60,
      "start_date": "2003-06-23",
      "completion_date": "2006-02-22",
      "has_results": false,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065143"
    },
    {
      "nct_id": "NCT04190550",
      "title": "Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Navtemadlin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2021-02-04",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04190550"
    },
    {
      "nct_id": "NCT01876953",
      "title": "Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "idarubicin",
          "type": "DRUG"
        },
        {
          "name": "dasatinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-09-13",
      "completion_date": "2018-04-25",
      "has_results": true,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01876953"
    },
    {
      "nct_id": "NCT02788201",
      "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "75 approved agents",
          "type": "DRUG"
        },
        {
          "name": "COXEN",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2017-03-27",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2020-11-06",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788201"
    },
    {
      "nct_id": "NCT00038649",
      "title": "Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelogenous Leukemia, Chronic, Chronic Phase"
      ],
      "interventions": [
        {
          "name": "Gleevec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2001-06",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038649"
    },
    {
      "nct_id": "NCT00549835",
      "title": "Acupuncture for Mucositis Pain in Cancer Care",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mucositis",
        "Pain",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Real Acupuncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Sham Acupuncture",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-08",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2015-04-08",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00549835"
    },
    {
      "nct_id": "NCT00103285",
      "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Childhood B Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Thioguanine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "1 Year to 9 Years"
      },
      "enrollment_count": 5377,
      "start_date": "2005-04-11",
      "completion_date": "2021-03-31",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-11-14T09:12:58.689Z",
      "location_count": 210,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00103285"
    }
  ]
}